Precision’s Dr. Dominic Galante will moderate the Quality Conversations Breakfast session on Day 2 of the NCQA Health Innovation Summit. “Digital Reshaping of the Diabetes Health-Care Ecosystem” will explore the promise of leveraging patient-generated data from CGMs to improve diabetes care, health equity, and the potential to augment diabetes quality measures that are reported and tracked by quality organizations. November 1 at 7:30AM ET.
Learn how to make your brands’ market access a top advantage over the competition. Join PRECISION’s Jon Bambalas, Jeff Becker and Thad Nowakowski at this year’s Managed Markets & Account Management Strategies Conference for “Make Market Access Your Brand’s Super Power,” October 27 at 9:30 AM CT.
Patient support programs, like HUB services, Patient Assistance Programs (PAP), Bridge programs or copay support, have become increasingly important in making prescription drugs more affordable and accessible. Yet an IQVIA study found that 31% of patients abandon their prescription if a coupon is not available compared with only 12% of new patients walked away from their prescriptions if a copay coupon was available to them.
Prescription abandonment continues to be a significant issue.
In this insightful webinar from PRECISIONxtract, you’ll hear how life science brand leaders can leverage EHR systems to dramatically increase successful enrollment for patient support programs.
Attendees will hear about:
Join us for this unique, solution-based discussion— a great fit for pharma manufacturers looking to get their brands’ patient resources in front of HCPs where those HCPs are in the moment of care — inside the EHR!
At this years Meeting on the Mesa’s conference, Anshul Mangal: President (Precision ADVANCE and Project Farma) sat down with leading industry experts to discuss the future of cell and gene therapies.
This panel, sponsored by Precision ADVANCE, will feature insights from industry leaders on the future of advanced therapies including innovations in clinical trials, going from treating rare diseases to prevalent conditions, and implementing next-generation gene-editing technologies. The panelists will also discuss manufacturing and talent bottlenecks and the evolution of reimbursement payment models.
Moderated by Anshul Mangal (President of Project Farma & Precision ADVANCE), this discussion will feature insights from Stewart Abbot: (Chief Scientific Officer, Turnstone Biologics), Andrew Knudten: (Chief Operating Officer, Jaguar Gene Therapy), Laura Lande-Diner: (Chief Business Officer, Satellite Bio), Robert Peters: (Chief Scientific Officer, Ensoma), and Deborah Phippard: (Chief Scientific Officer, Precision for Medicine).
In the last five years, 83 novel oncology substances have launched – oncology PMPM spend is now the highest among medical benefit categories, with 105% growth anticipated by 2024. As these numbers suggest, oncology is a key area of focus for payers, who are willing to invest resources to support appropriate utilization, but who struggle to keep up with the rapidly evolving science.
Join a discussion with PRECISIONvalue’s Access Experience Team (AET), comprised of former payers, to hear their insights on current trends in oncology payer management, payer response, payer management strategies, and the evolution of value-based care.
Moderated by PRECISIONvalue VP and Access Experience Team Director Ryan Cox, this one hour webinar will feature two of Precision’s senior oncology subject matter experts, Janet Serluco and Jennifer Williams.
Attendees of this webinar will come away with an understanding of:
In addition to the expert conversation, a live Q&A will conclude the webinar.
Doctors say it to sales reps all the time: “I like your drug and want to write it, but I can’t.” Where does your rep go from there?
New research indicates that 50% of an HCPs’ prescribing decision is based on their perception of accessibility. (But perception and reality can be two vastly different things.)
Marketers can’t change how accessible their products are, but they can change how HCPs view their brands’ accessibility on healthcare plans. In this webinar, you’ll hear about:
This solution-focused, truth-packed session is a great fit for market access marketers, brand marketers and sales leaders who are interested in making their brands’ market access a top advantage over the competition.
In this upcoming one-hour webinar, PRECISONadvisors Vice President Richard Macaulay will moderate a lively discussion with our panel of European payer experts as they examine the next generation of gene therapies, and weigh considerations for policy makers as well as manufacturers.
Issues to be discussed by the panel will include:
-Gene therapy treatments for diseases that take years to develop (e.g. Huntington’s Disease, Prion diseases)
-Gene Therapies to prevent development of diseases in genetically susceptible individuals (e.g. early-onset familial Alzheimer’s disease)
-Gene therapies to be used in utero (with the potential to treat lethal and morbid perinatal diseases before birth, as well as potentially using existing gene therapies much earlier in disease progression).
The discussion will conclude with a live Q&A.
Want to boost sales with HCP specific market access pull-through messaging tailored to your patient population? Discover how Access Genius can drive radical brand prescription growth and amplify sales with a 4:1 proven ROI.
Download the Infographic here to learn more!
The November Events Calendar is here! Stay up to date with all of the upcoming Precision conferences, on-demand events and recent thought leadership!
The October Events Calendar is here! Stay up to date with all of the upcoming Precision conferences, on-demand events and recent thought leadership!
The Precision Value & Health family of brands is now Precision AQ
Precision AQ helps life sciences companies navigate the complexities of commercialization across a product’s lifecycle. Our team is comprised of experts, advisors, and creators working to ensure patients have access to life-changing medicines.
Our global offerings include:
Our name, which stands for Precision Access Quotient, reflects our approach to removing barriers – fusing together science (IQ, or Intelligence Quotient) and empathy (EQ, or Emotional Quotient). The result is “AQ: Access Quotient”, a critical ingredient in navigating the therapy-to-patient journey informed by data-driven analytics and insights.
To find out more about our global services and our unified mission, empowering access to life-changing medicines for all, visit: Precision AQ
